TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07439653: A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Sponsor: TORL Biotherapeutics, LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 155 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$11,545,380

Rescue Site Savings

+$7,618,380

Unlock Full NCT07439653 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07439653 Rescue Dossier →